Cargando…
Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
Autores principales: | Scarton, Mathilde, Oppenheimer, Anne, Chaïbi, Khalil, Dreyfuss, Didier, Gaudry, Stéphane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489288/ https://www.ncbi.nlm.nih.gov/pubmed/31036047 http://dx.doi.org/10.1186/s13054-019-2447-0 |
Ejemplares similares
-
Personalization of renal replacement therapy initiation: a secondary analysis of the AKIKI and IDEAL-ICU trials
por: Grolleau, François, et al.
Publicado: (2022) -
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020) -
Renal Replacement Therapy in a World of Constraints: Lessons from the COVID-19 Pandemic
por: Gaudry, Stephane, et al.
Publicado: (2023) -
Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014) -
Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
por: Filev, Rumen, et al.
Publicado: (2022)